retatrutide ly3437943 phase 2 trial obesity nejm 2023 Results from a new of (LY3437943; Eli Lilly) found that participants had considerable decreases in body weight at week 48, although this depended on the dose and varied due to Retatrutide (LY3437943) - Phoenix Peptide

Disordered Eating History Women with history of anorexia, bulimia, or binge eating disorder require careful consideration before starting Retatrutide

The dosage used in that trial was 10 billion CFU daily

By the end of week four, we know whether the patient tolerates the GLP-1 piece and we have a stable dose to layer onto

1.1 placebo Moderate-to-severe depression (PHQ-9 10): remission 52% vs

GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GI GI GLP-1GI GIGlycemic Index GIGLP-1 GI GI GIGLP-1 GLP-1 GLP-1 GLP-1 GI GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 1 1202530g GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1GLP-1 GLP-1 2025 EPADHA GI GLP-1 GLP-12 GLP-1 URL GLP-1FDA